全文获取类型
收费全文 | 126566篇 |
免费 | 10919篇 |
国内免费 | 8217篇 |
专业分类
耳鼻咽喉 | 1030篇 |
儿科学 | 1564篇 |
妇产科学 | 2322篇 |
基础医学 | 14841篇 |
口腔科学 | 2063篇 |
临床医学 | 16451篇 |
内科学 | 20802篇 |
皮肤病学 | 1453篇 |
神经病学 | 6932篇 |
特种医学 | 4351篇 |
外国民族医学 | 72篇 |
外科学 | 13128篇 |
综合类 | 19065篇 |
现状与发展 | 24篇 |
一般理论 | 5篇 |
预防医学 | 7835篇 |
眼科学 | 3666篇 |
药学 | 12845篇 |
116篇 | |
中国医学 | 6082篇 |
肿瘤学 | 11055篇 |
出版年
2024年 | 351篇 |
2023年 | 1829篇 |
2022年 | 4670篇 |
2021年 | 5882篇 |
2020年 | 4243篇 |
2019年 | 4073篇 |
2018年 | 4135篇 |
2017年 | 3698篇 |
2016年 | 3469篇 |
2015年 | 5227篇 |
2014年 | 6559篇 |
2013年 | 6105篇 |
2012年 | 8931篇 |
2011年 | 9791篇 |
2010年 | 5974篇 |
2009年 | 4746篇 |
2008年 | 6535篇 |
2007年 | 6522篇 |
2006年 | 6564篇 |
2005年 | 6489篇 |
2004年 | 4490篇 |
2003年 | 4238篇 |
2002年 | 3624篇 |
2001年 | 3273篇 |
2000年 | 3351篇 |
1999年 | 3474篇 |
1998年 | 2294篇 |
1997年 | 2198篇 |
1996年 | 1574篇 |
1995年 | 1471篇 |
1994年 | 1275篇 |
1993年 | 823篇 |
1992年 | 1229篇 |
1991年 | 1078篇 |
1990年 | 935篇 |
1989年 | 825篇 |
1988年 | 712篇 |
1987年 | 668篇 |
1986年 | 508篇 |
1985年 | 463篇 |
1984年 | 250篇 |
1983年 | 178篇 |
1982年 | 119篇 |
1981年 | 116篇 |
1980年 | 76篇 |
1979年 | 120篇 |
1978年 | 59篇 |
1976年 | 52篇 |
1975年 | 55篇 |
1974年 | 65篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
评估玻璃体切割联合内界膜剥除对糖尿病性黄斑水肿(DME)的疗效。方法:回顾性病例对照研究。2014年6月至2017年1月间因糖尿病视网膜病变合并玻璃体积血或增殖病变于温州医科大学附属眼视光医院杭州院区行玻璃体切割手术治疗,且术前或术中经光学相干断层扫描(OCT)检查确诊合并DME的患者31例(33眼)纳入研究。16例(18眼)术中联合内界膜剥除作为剥膜组,15例(15眼)仅接受玻璃体切割手术治疗者作为对照组。所有手术均由同一医师主刀完成。术后1、3个月随访时复查OCT,对比观察黄斑中心厚度(CMT)和视力的术后变化情况。随访中CMT和最佳矫正视力(BCVA)比较采用重复测量方差分析,组间CMT和BCVA比较采用独立样本t检验。结果:手术前,手术后1、3个月2组间比较LogMAR视力总体差异有统计学意义(F=15.93,P<0.001)。术后 1个月时剥膜组BCVA高于对照组(t=2.55,P=0.02),但术后3个月时2组间差异无统计学意义(t=0.82, P=0.42)。手术前,手术后1、3个月CMT总体差异无统计学意义(F=2.85,P=0.065)。术后1、3个月时,剥膜组的CMT均低于对照组,2组间差异均有统计学意义(t=2.24,P=0.03;t=3.79,P=0.001)。术后1个月时,剥膜组有效(与术前比CMT减少20%以上)、无效(变化不超过20%)及恶化(增厚超过 20%)的例数分别为8、6、4例,术后3个月时则分别为11、5、2例,与对照组相比,术后1个月时组间差异无统计学意义(Z=-1.687,P=0.092),术后3个月时剥膜组DME改善有效比例明显高于对照组,组间差异有统计学意义(Z=-2.177,P=0.029)。结论:对于非牵拉性DME,内界膜剥除有助于术后早期DME消退。 相似文献
32.
本研究拟探讨染料木黄酮对前列腺癌细胞LNCaP和CWR22RV1的增殖、迁移和侵袭能力的影响。一、材料与方法1.材料:前列腺癌细胞株LNCaP和CWR22RV1(中国科学院上海生命科学研究院);Genistein(天津科瑞泰科技有限公司);RPMI 1640、胎牛血清(FBS)、胰蛋白酶(美国Gibco公司);E-钙黏蛋白(E-cadherin)、N-钙黏蛋白(N-cadherin)、波形蛋白(Vimentin,Abcam公司);聚氰基丙烯酸正丁酯(BCA)试剂盒、十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)上样缓冲液(×5)及蛋白质印迹法(Western blot)试剂盒(上海市碧云天生物公司);2.实验方法:采用噻唑蓝(MTT)实验、划痕实验和Transwell实验检测Genistein对细胞增殖、迁移及侵袭能力的影响。采用Western blot检测E-cadherin、N-cadherin、Vimentin、CD44和Oct-4的表达水平。 相似文献
33.
Jae Eun Choi Tyler Werbel Zhenping Wang Chia Chi Wu Tony L. Yaksh Anna Di Nardo 《Journal of dermatological science》2019,93(1):58-64
Background
Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.Objectives
To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.Methods
Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.Results
Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.Conclusions
These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study. 相似文献34.
35.
Zhi-Ran Shi Hua Zhang Xian-Yuan Zhang Wen-Bin Wu 《Journal of Asian natural products research》2016,18(5):443-449
Two new bisamides, aglaiamides A (1) and B (2), along with three known ones (3–5), were isolated from the leaves of Aglaia perviridis. Their structures were established on the basis of detailed spectroscopic analyses. 相似文献
36.
Clinical Spectrum of Capillary Malformation–Arteriovenous Malformation Syndrome Presenting to a Pediatric Dermatology Practice: A Retrospective Study
下载免费PDF全文
![点击此处可从《Pediatric dermatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Nicole A. Weitz M.D. Christine T. Lauren M.D. Gerald G. Behr M.D. June K. Wu M.D. Jessica J. Kandel M.D. Philip M. Meyers M.D. Sally Sultan M.D. Kwame Anyane‐Yeboa M.D. Kimberly D. Morel M.D. Maria C. Garzon M.D. 《Pediatric dermatology》2015,32(1):76-84
Capillary malformation–arteriovenous malformation syndrome (CM‐AVM) is an autosomal dominant disorder caused by RASA1 mutations. The prevalence and phenotypic spectrum are unknown. Evaluation of patients with multiple CMs is challenging because associated AVMs can be life threatening. The objective of this study was to describe the clinical characteristics of children presenting with features of CM‐AVM to an academic pediatric dermatology practice. After institutional review board approval was received, a retrospective chart review was performed of patients presenting between 2009 and 2012 with features of CM‐AVM. We report nine cases. Presenting symptoms ranged from extensive vascular stains and cardiac failure to CMs noted incidentally during routine skin examination. All demonstrated multiple CMs, two had Parkes Weber syndrome, and two had multiple infantile hemangiomas. Seven patients had family histories of multiple CMs; three had family histories of large, atypical CMs. Six had personal or family histories of AVMs. Genetic evaluation was recommended for all and was pursued by six families; four RASA1 mutations were identified, including one de novo. Consultations with neurology, cardiology, and orthopedics were recommended. Most patients (89%) have not required treatment to date. CM‐AVM is an underrecognized condition with a wide clinical spectrum that often presents in childhood. Further evaluation may be indicated in patients with multiple CMs. This study is limited by its small and retrospective nature. 相似文献
37.
38.
39.
40.